Protagonist Therapeutics (PTGX) stock Forecast for 2021 – 2025

Protagonist Therapeutics (PTGX) stock Forecast for 2022 – 2026

Last update: 05-17-2022, 5:11

Sector: Healthcare

The share price of Protagonist Therapeutics, Inc. (PTGX) now

What analysts predict:: $47.14

52-week high/low: $50.54 / $7.87

50/200 Day Moving Average: $19.83 / $30.29

This figure corresponds to the average price over the previous 50/200 days. For Protagonist Therapeutics stocks, the 50-day moving average is the support level today.

For Protagonist Therapeutics stocks, the 200-day moving average is the resistance level today.

Are you interested in Protagonist Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Protagonist Therapeutics stock price in 2022, 2023, 2024, 2025, 2026. How much will one Protagonist Therapeutics share be worth in 2022 - 2026?

When should I take profit in Protagonist Therapeutics stock? When should I record a loss on Protagonist Therapeutics stock? What are analysts' forecasts for Protagonist Therapeutics stock? What is the future of Protagonist Therapeutics stock?

We forecast Protagonist Therapeutics stock performance using neural networks based on historical data on Protagonist Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Protagonist Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)

The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Protagonist Therapeutics shares. This happens once a day.




Historical and forecast chart of Protagonist Therapeutics stock

The chart below shows the historical price of Protagonist Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Protagonist Therapeutics stock price can be found in the table below.

Long-term forecasts by years.

Protagonist Therapeutics daily forecast for a month

Date Target Pes. Opt. Vol., %
May 19 29.91 29.72 30.21 1.64
May 20 29.96 29.73 30.48 2.52
May 21 30.37 30.17 30.61 1.45
May 22 30.25 29.76 30.80 3.48
May 23 30.55 29.95 30.78 2.77
May 24 30.53 30.07 30.75 2.27
May 25 30.41 29.85 30.82 3.23
May 26 30.05 29.72 30.37 2.17
May 27 30.33 29.86 31.01 3.83
May 28 30.18 29.58 30.59 3.40
May 29 29.27 29.06 29.71 2.26
May 30 29.84 29.47 30.51 3.53
May 31 29.55 28.91 30.22 4.55
Jun 01 29.92 29.38 30.41 3.49
Jun 02 30.68 30.31 31.19 2.88
Jun 03 31.35 31.11 31.70 1.90
Jun 04 31.61 30.85 32.26 4.56
Jun 05 31.90 31.52 32.65 3.59
Jun 06 32.07 31.41 32.56 3.66
Jun 07 32.28 31.65 32.88 3.92
Jun 08 32.40 31.92 33.23 4.09
Jun 09 31.94 31.39 32.33 3.00
Jun 10 32.93 32.50 33.41 2.79
Jun 11 33.21 32.55 33.94 4.28
Jun 12 33.22 32.61 33.83 3.72
Jun 13 33.26 32.58 33.47 2.74
Jun 14 33.22 32.58 34.00 4.34
Jun 15 33.60 33.25 34.41 3.49
Jun 16 33.53 32.67 34.04 4.20
Jun 17 32.68 32.15 33.20 3.29

Protagonist Therapeutics Daily Price Targets


Protagonist Therapeutics Stock Forecast 05-19-2022.

Forecast target price for 05-19-2022: $29.91. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 1.616%.

Pessimistic target level: 29.72

Optimistic target level: 30.21


Protagonist Therapeutics Stock Forecast 05-20-2022.

Forecast target price for 05-20-2022: $29.96. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.454%.

Pessimistic target level: 29.73

Optimistic target level: 30.48


Protagonist Therapeutics Stock Forecast 05-21-2022.

Forecast target price for 05-21-2022: $30.37. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 1.429%.

Pessimistic target level: 30.17

Optimistic target level: 30.61


Protagonist Therapeutics Stock Forecast 05-22-2022.

Forecast target price for 05-22-2022: $30.25. Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 3.363%.

Pessimistic target level: 29.76

Optimistic target level: 30.80


Protagonist Therapeutics Stock Forecast 05-23-2022.

Forecast target price for 05-23-2022: $30.55. Positive dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.699%.

Pessimistic target level: 29.95

Optimistic target level: 30.78


Protagonist Therapeutics Stock Forecast 05-24-2022.

Forecast target price for 05-24-2022: $30.53. Negative dynamics for Protagonist Therapeutics shares will prevail with possible volatility of 2.224%.

Pessimistic target level: 30.07

Optimistic target level: 30.75


PTGX (PTGX) Monthly Stock Prediction for 2022

Month Target Pes. Opt. Vol., %
Jun. 32.35 29.28 34.56 15.28
Jul. 35.10 32.24 36.11 10.73
Aug. 35.78 33.03 37.80 12.61
Sep. 33.63 32.18 35.73 9.94
Oct. 34.08 31.62 35.26 10.32
Nov. 35.02 33.80 37.20 9.15
Dec. 34.09 31.88 35.20 9.42

Protagonist Therapeutics forecast for this year


Protagonist Therapeutics Stock Prediction for Jun 2022

An uptrend is forecast for this month with an optimal target price of $32.3479. Pessimistic: $29.28. Optimistic: $34.56


Protagonist Therapeutics Stock Prediction for Jul 2022

An uptrend is forecast for this month with an optimal target price of $35.1039. Pessimistic: $32.24. Optimistic: $36.11


Protagonist Therapeutics Stock Prediction for Aug 2022

An uptrend is forecast for this month with an optimal target price of $35.7779. Pessimistic: $33.03. Optimistic: $37.80


Protagonist Therapeutics Stock Prediction for Sep 2022

An downtrend is forecast for this month with an optimal target price of $33.6312. Pessimistic: $32.18. Optimistic: $35.73


Protagonist Therapeutics Stock Prediction for Oct 2022

An uptrend is forecast for this month with an optimal target price of $34.0752. Pessimistic: $31.62. Optimistic: $35.26


Protagonist Therapeutics Stock Prediction for Nov 2022

An uptrend is forecast for this month with an optimal target price of $35.0156. Pessimistic: $33.80. Optimistic: $37.20


Protagonist Therapeutics Stock Prediction for Dec 2022

An downtrend is forecast for this month with an optimal target price of $34.0912. Pessimistic: $31.88. Optimistic: $35.20




Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2023

Month Target Pes. Opt. Vol., %
Jan 32.82 32.00 35.78 10.57
Feb 32.00 30.54 34.95 12.63
Mar 32.92 30.35 34.46 11.92
Apr 29.24 27.42 30.19 9.18
May 29.74 27.59 30.95 10.84
Jun 33.27 30.23 34.39 12.07
Jul 36.14 32.72 39.13 16.40
Aug 39.83 37.87 43.37 12.67
Sep 39.40 38.26 42.61 10.21
Oct 42.94 41.35 46.40 10.88
Nov 41.66 38.61 43.51 11.26
Dec 43.71 40.24 47.69 15.62

Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jan 41.03 39.55 43.74 9.57
Feb 38.96 36.11 40.69 11.26
Mar 38.17 35.74 40.00 10.65
Apr 39.36 37.75 43.14 12.48
May 39.97 38.49 41.99 8.34
Jun 44.63 42.38 47.46 10.72
Jul 47.84 45.14 50.59 10.78
Aug 51.05 49.09 54.91 10.60
Sep 46.46 43.73 49.58 11.81
Oct 43.78 40.58 47.46 14.50
Nov 41.84 39.73 43.85 9.39
Dec 39.93 36.58 43.24 15.40



Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 39.21 37.09 42.65 13.02
Feb 41.33 37.81 45.15 16.26
Mar 46.24 43.08 49.51 13.00
Apr 45.63 43.11 49.84 13.51
May 48.37 45.00 50.46 10.81
Jun 54.00 50.11 58.73 14.67
Jul 52.44 47.85 55.78 14.22
Aug 56.41 54.31 58.44 7.07
Sep 52.01 48.76 56.06 13.02
Oct 49.26 45.83 52.81 13.21
Nov 50.44 46.75 52.86 11.56
Dec 48.99 45.29 52.93 14.44

Protagonist Therapeutics (PTGX) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 53.93 50.43 55.48 9.10
Feb 56.13 51.88 58.96 12.00
Mar 57.54 55.40 60.30 8.13
Apr 56.58 54.06 58.14 7.01
May 60.58 59.05 65.82 10.27
Jun 62.25 57.77 67.11 13.91
Jul 67.56 61.64 72.75 15.27
Aug 71.29 68.98 74.62 7.57
Sep 73.17 66.93 78.96 15.23
Oct 72.12 69.95 76.36 8.39
Nov 70.12 65.83 74.75 11.93
Dec 71.56 64.86 73.79 12.10

Protagonist Therapeutics information and performance

“Protagonist Therapeutics, Inc.” is a clinical stage biopharmaceutical company with a peptide technology platform focused on the discovery and development of new chemical entities (NECs) to meet significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. His main focus is on the development of oral peptide formulations that target biological pathways, also targeting commercially available injectable antibodies. PTG-100 is an oral peptide product of an alpha-4-beta-7 (a4b7) integrin antagonist candidate who has completed a phase I clinical trial in normal healthy volunteers (NHVs). PTH-100 is being developed for the treatment of moderate to severe ulcerative colitis (UC). PTG-200 is an oral interleukin-23 (IL-23R) receptor antagonist being developed for the treatment of moderate to severe Crohn’s disease. PTG-300 is an injectable hepcidin mimetic for the treatment of rare conditions associated with iron overload.

Protagonist Therapeutics Address

7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, US

Market Capitalization: 428 661 000 $

Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.

EBITDA: -70 271 000 $

EBITDA is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: N/A

Price/earnings to growth

DPS: N/A

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: N/A

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -2.71

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: N/A

Quarterly Revenue Growth YOY: 0.525

Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: -

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 2.257

Enterprise Value (EV) /Revenue

EV To EBITDA: -

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 48656200

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A

Percent Insiders: N/A

Percent Institutions: N/A




Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.